Experimental infection and protection against ... - TI Pharma
Experimental infection and protection against ... - TI Pharma Experimental infection and protection against ... - TI Pharma
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections Figure 3. Production of IFNγ, TNF and IL-2 by CD3+ T-lymphocytes after in vitro restimulation with NF135.C10 or NF54 determined before and after challenge of volunteers. Time points displayed are: before challenge (C-1), five days after challenge (C+5), on day of treatment (DT) and 35 and 140 days after challenge. PBMCs were stimulated for 24-hour with asexual stage parasites (PfRBC) of NF135.C10 or NF54. Numbers of (A,D,G) IFNγ (B,E,H) TNF and (C,F,I) IL-2 producing cells are depicted as percentages of total T-lymphocytes. (A-C) Production of cytokines after homologous stimulation of cells taken before and after challenge. Cells of volunteers infected with NF135.C10 (open red circles) were stimulated with NF135.C10 PfRBC. Cells of volunteers infected with NF54 (closed black circles) were stimulated with NF54 PfRBC. (D-F) Production of cytokines after homologous (NF135.C10, closed red circles) or heterologous (NF54, open grey circles) stimulation of PBMCs of volunteers before and after challenge with NF135.C10. (G-I) Production of cytokines after homologous (NF54, closed black circles) or heterologous (NF135.C10, open grey circles) stimulation of PBMCs of volunteers before and after challenge with NF54. Symbols indicate individual values from volunteers (A-C) or represent group medians with interquartile range (D-I). 141
142 Chapter 7 Figure 4. Contribution of different cell types to the total number of IFNγ-producing cells upon stimulation with either homologous or heterologous PfRBC. Mean percentage contribution to the total response are displayed for PBMCs of volunteers successfully infected with NF135.C10 (n=3) or NF54 (n=4) when re-stimulated in vitro with either NF135.C10 or NF54 PfRBC. Columns show mean percentage contribution on day 35 post-challenge of (A) NK cells (CD3 - CD56 + ), NK-T γδ-T + cells (CD3 + γδ-T + CD56 + ), NK-T cells (CD3 + γδ-T - CD56 + ), γδ-T cells (CD3 + γδ-T + CD56 - ), αβ-T CD4 cells (CD3 + γδ-T - CD4 + ), and αβ-T CD8 cells (CD3 + γδ-T - CD8 + ) and (B) effector memory (EM) cells (CD3 + , CD45RO + , CD62L - ), central memory (CM) cells (CD3 + , CD45RO + , CD62L + ) and naive T-lymphocytes (CD3 + , CD45RO - ). Responses to uninfected red blood cells are subtracted from responses to PfRBC per contributing cell type.
- Page 91 and 92: 90 Chapter 4 positively correlated
- Page 93 and 94: 92 Chapter 4 Acknowledgements The a
- Page 95 and 96: 94 Chapter 4 determinant of subsequ
- Page 98 and 99: Chapter 5 Comparison of clinical an
- Page 100 and 101: Comparison of clinical and parasito
- Page 102 and 103: Comparison of clinical and parasito
- Page 104 and 105: Comparison of clinical and parasito
- Page 106 and 107: Comparison of clinical and parasito
- Page 108 and 109: Comparison of clinical and parasito
- Page 110 and 111: Comparison of clinical and parasito
- Page 112 and 113: Comparison of clinical and parasito
- Page 114 and 115: Comparison of clinical and parasito
- Page 116 and 117: Comparison of clinical and parasito
- Page 118 and 119: Chapter 6 Efficacy of pre-erythrocy
- Page 120 and 121: Efficacy of pre-erythrocytic and bl
- Page 122 and 123: Efficacy of pre-erythrocytic and bl
- Page 124 and 125: Efficacy of pre-erythrocytic and bl
- Page 126 and 127: Efficacy of pre-erythrocytic and bl
- Page 128 and 129: Efficacy of pre-erythrocytic and bl
- Page 130 and 131: Chapter 7 NF135.C10: a new Plasmodi
- Page 132 and 133: NF135.C10: a new Plasmodium falcipa
- Page 134 and 135: NF135.C10: a new Plasmodium falcipa
- Page 136 and 137: NF135.C10: a new Plasmodium falcipa
- Page 138 and 139: NF135.C10: a new Plasmodium falcipa
- Page 140 and 141: NF135.C10: a new Plasmodium falcipa
- Page 144 and 145: NF135.C10: a new Plasmodium falcipa
- Page 146 and 147: NF135.C10: a new Plasmodium falcipa
- Page 148 and 149: NF135.C10: a new Plasmodium falcipa
- Page 150 and 151: NF135.C10: a new Plasmodium falcipa
- Page 152 and 153: Chapter 8 Induction of malaria in v
- Page 154 and 155: Induction of malaria in volunteers
- Page 156 and 157: Induction of malaria in volunteers
- Page 158 and 159: Induction of malaria in volunteers
- Page 160 and 161: Induction of malaria in volunteers
- Page 162 and 163: Induction of malaria in volunteers
- Page 164 and 165: Induction of malaria in volunteers
- Page 166 and 167: Induction of malaria in volunteers
- Page 168 and 169: Induction of malaria in volunteers
- Page 170 and 171: Induction of malaria in volunteers
- Page 172: Section 3 Whole parasite inoculatio
- Page 175 and 176: 174 Chapter 9 Abstract An effective
- Page 177 and 178: 176 Chapter 9 Figure 1. Study desig
- Page 179 and 180: 178 Chapter 9 followed by five iden
- Page 181 and 182: 180 Chapter 9 Figure 2. Parasitemia
- Page 183 and 184: 182 Chapter 9 Test Day I-1 Day C-1
- Page 185 and 186: 184 Chapter 9 strain P. falciparum-
- Page 187 and 188: 186 Chapter 9 protective role in ot
- Page 189 and 190: 188 Chapter 9 References 1. Greenwo
- Page 191 and 192: 190 Chapter 9 27. Orjih AU. Acute m
142 Chapter 7<br />
Figure 4. Contribution of different cell types to the total number of IFNγ-producing<br />
cells upon stimulation with either homologous or heterologous PfRBC. Mean<br />
percentage contribution to the total response are displayed for PBMCs of volunteers<br />
successfully infected with NF135.C10 (n=3) or NF54 (n=4) when re-stimulated in<br />
vitro with either NF135.C10 or NF54 PfRBC. Columns show mean percentage<br />
contribution on day 35 post-challenge of (A) NK cells (CD3 - CD56 + ), NK-T γδ-T + cells<br />
(CD3 + γδ-T + CD56 + ), NK-T cells (CD3 + γδ-T - CD56 + ), γδ-T cells (CD3 + γδ-T + CD56 - ), αβ-T<br />
CD4 cells (CD3 + γδ-T - CD4 + ), <strong>and</strong> αβ-T CD8 cells (CD3 + γδ-T - CD8 + ) <strong>and</strong> (B) effector<br />
memory (EM) cells (CD3 + , CD45RO + , CD62L - ), central memory (CM) cells (CD3 + ,<br />
CD45RO + , CD62L + ) <strong>and</strong> naive T-lymphocytes (CD3 + , CD45RO - ). Responses to<br />
uninfected red blood cells are subtracted from responses to PfRBC per contributing<br />
cell type.
Change language